2012 Fiscal Year Final Research Report
Development of a novel treatment strategy that targets erythropoietin receptors and HIF
| Project/Area Number |
22590800
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Circulatory organs internal medicine
|
|---|
| Research Institution | Tohoku University |
|---|
Principal Investigator |
KAGAYA Yutaka 東北大学, 大学院・医学系研究科, 教授 (90250779)
|
|---|
| Co-Investigator(Renkei-kenkyūsha) |
TAKEDA Morihiko 東北大学, 病院, 助教 (30375084)
|
|---|
| Project Period (FY) |
2010 – 2012
|
| Keywords | 心不全 / 心肥大 / エリスロポエチン / HIF |
|---|
| Research Abstract |
Our objective was to determine whether novel strategies to treat heart failure with recombinant human erythropoietin (EPO) and a prolyl hydroxylase (PHD) inhibitor that stabilizes hypoxia-inducible factor (HIF) are useful. EPO protected the pressure-overload induced hypertrophied left ventricle in mice by maintaining left ventricular systolic function and improved the survival. The PHD inhibitor failed to demonstrate such a protective effect at least with the doses and treatment period usedin the present study. Further investigations are required to address the issue.
|
-
-
-
-
-
-
-
[Presentation] Prognostic significance of enhanced [^<18>F] fluorodeoxyglucose accumulation in the right ventricular free wall in patients with pulmonary hypertension2012
Author(s)
Tatebe S, Fukumoto Y, Sugimura K, Satoh K, Miura Y, Nochioka K, Aoki T, Yamamoto S, Wakayama-Oikawa M, Kagaya Y, Shimokawa H.
Organizer
Scientific Sessions of American Heart Association 2012
Place of Presentation
Los Angeles, U.S.A.
Year and Date
2012-11-05
-
-
-
-
-
